The latest lymphoma news
Researchers discover compound that fights leukaemia, lymphoma
Researchers at The University of Texas at El Paso, USA, have identified a novel pharmaceutical…
Browsing: Lymphoma
Germs can offset the effect of cancer therapy
The bacteria Staphylococcus aureus (S. aureus) can worsen the condition of patients with the lymphoma type Sezáry…
Hodgkin lymphoma prognosis, biology tracked with circulating tumour DNA
A Stanford Medicine-led, international study of hundreds of samples from patients with Hodgkin lymphoma has…
ASH 2023: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall…
ASH 2023: Study shows CAR-T cell therapy safe, effective even for high-risk patients
CAR-T cell therapy is a safe and effective treatment for diffuse large B-cell lymphoma (DLBCL),…
ASH 2023: Cell therapy appears safe and effective for lymphoma in remission
A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami…
ASH 2023: Combination immunotherapy produces high response rate in early results of trial targeting high-risk follicular lymphoma
Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University…
ASH 2023: Venetoclax with standard chemo-immunotherapy induced a high response rate as first-line treatment for mantle cell lymphoma and was generally well tolerated
The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate…
Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)
This content is password-protected. To view it, please enter the password below. Password:
New resource to help families understand paediatric Hodgkin lymphoma
The National Comprehensive Cancer Network® (NCCN®) today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma…